{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T17:32:39Z","timestamp":1793467959576,"version":"4.5.0"},"reference-count":36,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2023,8,1]]},"abstract":"\n Importance<\/jats:title>\n Ocrelizumab, a humanized monoclonal antibody targeted against CD20+ B cells, reduces the frequency of relapses by 46% and disability worsening by 40% compared with interferon beta 1a in relapsing-remitting multiple sclerosis (MS). Rituximab, a chimeric monoclonal anti-CD20 agent, is often prescribed as an off-label alternative to ocrelizumab.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate whether the effectiveness of rituximab is noninferior to ocrelizumab in relapsing-remitting MS.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This was an observational cohort study conducted between January 2015 and March 2021. Patients were included in the treatment group for the duration of study therapy and were recruited from the MSBase registry and Danish MS Registry (DMSR). Included patients had a history of relapsing-remitting MS treated with ocrelizumab or rituximab, a minimum 6 months of follow-up, and sufficient data to calculate the propensity score. Patients with comparable baseline characteristics were 1:6 matched with propensity score on age, sex, MS duration, disability (Expanded Disability Status Scale), prior relapse rate, prior therapy, disease activity (relapses, disability accumulation, or both), magnetic resonance imaging lesion burden (missing values imputed), and country.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Treatment with ocrelizumab or rituximab after 2015.<\/jats:p>\n <\/jats:sec>\n \n Main outcomes and Measures<\/jats:title>\n Noninferiority comparison of annualized rate of relapses (ARRs), with a prespecified noninferiority margin of 1.63 rate ratio. Secondary end points were relapse and 6-month confirmed disability accumulation in pairwise-censored groups.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of the 6027 patients with MS who were treated with ocrelizumab or rituximab, a total of 1613 (mean [SD] age; 42.0 [10.8] years; 1089 female [68%]) fulfilled the inclusion criteria and were included in the analysis (898 MSBase, 715 DMSR). A total of 710 patients treated with ocrelizumab (414 MSBase, 296 DMSR) were matched with 186 patients treated with rituximab (110 MSBase, 76 DMSR). Over a pairwise censored mean (SD) follow-up of 1.4 (0.7) years, the ARR ratio was higher in patients treated with rituximab than in those treated with ocrelizumab (rate ratio, 1.8; 95% CI, 1.4-2.4; ARR, 0.20 vs 0.09;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). The cumulative hazard of relapses was higher among patients treated with rituximab than those treated with ocrelizumab (hazard ratio, 2.1; 95% CI, 1.5-3.0). No difference in the risk of disability accumulation was observed between groups. Results were confirmed in sensitivity analyses.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n In this noninferiority comparative effectiveness observational cohort study, results did not show noninferiority of treatment with rituximab compared with ocrelizumab. As administered in everyday practice, rituximab was associated with a higher risk of relapses than ocrelizumab. The efficacy of rituximab and ocrelizumab administered at uniform doses and intervals is being further evaluated in randomized noninferiority clinical trials.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaneurol.2023.1625","type":"journal-article","created":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T11:01:41Z","timestamp":1686567701000},"page":"789","source":"Crossref","is-referenced-by-count":75,"title":["Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis"],"prefix":"10.1001","volume":"80","author":[{"given":"Izanne","family":"Roos","sequence":"first","affiliation":[{"name":"Neuroimmunology Centre, Royal Melbourne Hospital, Melbourne, Victoria, Australia"},{"name":"CORe, Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Hughes","sequence":"additional","affiliation":[{"name":"Royal Victoria Hospital, Belfast, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"McDonnell","sequence":"additional","affiliation":[{"name":"Belfast City Hospital, Belfast, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles B.","family":"Malpas","sequence":"additional","affiliation":[{"name":"Neuroimmunology Centre, Royal Melbourne Hospital, Melbourne, Victoria, Australia"},{"name":"CORe, Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sifat","family":"Sharmin","sequence":"additional","affiliation":[{"name":"CORe, Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cavit","family":"Boz","sequence":"additional","affiliation":[{"name":"KTU Medical Faculty Farabi Hospital, Trabzon, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raed","family":"Alroughani","sequence":"additional","affiliation":[{"name":"Division of Neurology, Department of Medicine, Amiri Hospital, Sharq, Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serkan","family":"Ozakbas","sequence":"additional","affiliation":[{"name":"Dokuz Eylul University, Konak\/Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Buzzard","sequence":"additional","affiliation":[{"name":"Neuroimmunology Centre, Royal Melbourne Hospital, Melbourne, Victoria, Australia"},{"name":"Department of Neurology, Box Hill Hospital, Melbourne, Victoria, Australia"},{"name":"Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Skibina","sequence":"additional","affiliation":[{"name":"Department of Neurology, Box Hill Hospital, Melbourne, Victoria, Australia"},{"name":"Monash University, Melbourne, Victoria, Australia"},{"name":"Department of Neurology, The Alfred Hospital, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke","family":"van der Walt","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Alfred Hospital, Melbourne, Victoria, Australia"},{"name":"Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Butzkueven","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Alfred Hospital, Melbourne, Victoria, Australia"},{"name":"Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannette","family":"Lechner-Scott","sequence":"additional","affiliation":[{"name":"School of Medicine and Public Health, University Newcastle, Newcastle, New South Wales, Australia"},{"name":"Department of Neurology, John Hunter Hospital, Hunter New England Health, Newcastle, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Kuhle","sequence":"additional","affiliation":[{"name":"Departments of Medicine, Biomedicine, and Clinical Research, Neurologic Clinic and Policlinic, University Hospital and University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Terzi","sequence":"additional","affiliation":[{"name":"Medical Faculty, 19 Mayis University, Samsun, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Laureys","sequence":"additional","affiliation":[{"name":"Department of Neurology, Ghent University Hospital, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesbeth","family":"Van Hijfte","sequence":"additional","affiliation":[{"name":"Department of Neurology, Ghent University Hospital, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nevin","family":"John","sequence":"additional","affiliation":[{"name":"Department of Neurology, Monash Health, Melbourne, Victoria, Australia"},{"name":"Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Grammond","sequence":"additional","affiliation":[{"name":"CISSS Chaudi\u00e8re-Appalache, Levis, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Grand\u2019Maison","sequence":"additional","affiliation":[{"name":"Neuro Rive-Sud, Longueuil, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysun","family":"Soysal","sequence":"additional","affiliation":[{"name":"Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Voldsgaard","family":"Jensen","sequence":"additional","affiliation":[{"name":"Danish Multiple Sclerosis Center, Rigshospitalet Glostrup, Copenhagen University Hospital, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Vestergaard","family":"Rasmussen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina Bacher","family":"Svendsen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismael","family":"Barzinji","sequence":"additional","affiliation":[{"name":"Aalborg University Hospital, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helle Hvilsted","family":"Nielsen","sequence":"additional","affiliation":[{"name":"The Multiple Sclerosis Clinic, Department of Neurology, Odense University Hospital, Odense C, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Sejb\u00e6k","sequence":"additional","affiliation":[{"name":"Department of Neurology, Esbjerg Hospital, University Hospital of Southern Denmark, Esbjerg, Denmark"},{"name":"Department of Regional Health Research, University of Southern Denmark, Esbjerg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivagini","family":"Prakash","sequence":"additional","affiliation":[{"name":"Neurological Department, Viborg Hospital, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten Leif Munding","family":"Stilund","sequence":"additional","affiliation":[{"name":"Department of Neurology and Physiotherapy, G\u00f8dstrup Hospital, Herning, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arkadiusz","family":"Weglewski","sequence":"additional","affiliation":[{"name":"Neurology Department Herlev Hospital, Denmark"},{"name":"Faculty of Health and Medical Sciences, Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia Mubder","family":"Issa","sequence":"additional","affiliation":[{"name":"Department of Neurology, North Zealand Hospital, Hillerod, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Kant","sequence":"additional","affiliation":[{"name":"Hospital of Southern Jutland, University of Southern Denmark, Aabenraa, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finn","family":"Sellebjerg","sequence":"additional","affiliation":[{"name":"Danish Multiple Sclerosis Center, Rigshospitalet Glostrup, Copenhagen University Hospital, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orla","family":"Gray","sequence":"additional","affiliation":[{"name":"South Eastern HSC Trust, Belfast, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Magyari","sequence":"additional","affiliation":[{"name":"Danish Multiple Sclerosis Center, Rigshospitalet Glostrup, Copenhagen University Hospital, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Kalincik","sequence":"additional","affiliation":[{"name":"Neuroimmunology Centre, Royal Melbourne Hospital, Melbourne, Victoria, Australia"},{"name":"CORe, Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"MSBase Study GroupDanish MS Registry Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Antonio","family":"Cabrera-Gomez","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Roullet","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cees","family":"Zwanikken","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leontien","family":"Den braber-Moerland","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Barnett","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Hodgkinson","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Garber","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Slee","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"McCombe","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Taylor","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"MacDonell","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Massey","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Van Pesch","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Decoo","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Willekens","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yara","family":"Fragoso","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Prevost","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Prat","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Girard","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Grammond","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Larochelle","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwon","family":"Oh","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Lalive","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Gobbi","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Horakova","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Havrdova","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radek","family":"Ampapa","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Izquierdo","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Eichau","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose L.","family":"Sanchez-Menoyo","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Ramo-Tello","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"Blanco","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Saiz","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Besora","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahid","family":"Shaygannejad","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Cartechini","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Diamanti","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pia","family":"Amato","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Spitaleri","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Patti","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Chisari","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"D'Amico","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo Fermo","family":"Salvatore","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassem","family":"Yamout","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia J.","family":"Khoury","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Al-Asmi","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Jose Sa","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talal","family":"Al-Harbi","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Karabudak","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Recai","family":"Turkoglu","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Kilpatrick","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"King","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Lan","family":"Nguyen","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Dwyer","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mastura","family":"Monif","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Taylor","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine","family":"Baker","sequence":"additional","affiliation":[{"name":"for the MSBase Study GroupDanish MS Registry Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"7","key":"noi230035r2","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"issue":"3","key":"noi230035r3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab vs interferon beta-1a in relapsing multiple sclerosis.","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"noi230035r4","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/ane.12963","article-title":"Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden\u2014outlier or predecessor?","volume":"138","author":"Berntsson","year":"2018","journal-title":"Acta Neurol Scand"},{"issue":"20","key":"noi230035r5","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1212\/WNL.0000000000003331","article-title":"Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy.","volume":"87","author":"Salzer","year":"2016","journal-title":"Neurology"},{"issue":"8","key":"noi230035r6","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1177\/1352458517713668","article-title":"Comparative effectiveness of rituximab relative to IFN-\u00df or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry.","volume":"24","author":"Spelman","year":"2018","journal-title":"Mult Scler"},{"issue":"3","key":"noi230035r7","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1001\/jamaneurol.2017.4011","article-title":"Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis.","volume":"75","author":"Granqvist","year":"2018","journal-title":"JAMA Neurol"},{"issue":"8","key":"noi230035r8","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S1474-4422(22)00209-5","article-title":"Safety and efficacy of rituximab vs dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial.","volume":"21","author":"Svenningsson","year":"2022","journal-title":"Lancet Neurol"},{"issue":"2","key":"noi230035r9","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1001\/jama.2018.20588","article-title":"Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis.","volume":"321","author":"Brown","year":"2019","journal-title":"JAMA"},{"issue":"4","key":"noi230035r10","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1474-4422(17)30007-8","article-title":"Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.","volume":"16","author":"Kalincik","year":"2017","journal-title":"Lancet Neurol"},{"issue":"4","key":"noi230035r11","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1136\/jnnp-2018-319831","article-title":"Comparison of fingolimod, dimethyl fumarate, and teriflunomide for multiple sclerosis.","volume":"90","author":"Kalincik","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"noi230035r12","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1002\/pds.v29.10","article-title":"Rivaroxaban was found to be noninferior to warfarin in routine clinical care: A retrospective noninferiority cohort replication study.","volume":"29","author":"Althunian","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"noi230035r13","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1007\/s00586-016-4683-1","article-title":"The effectiveness of decompression alone compared with additional fusion for lumbar spinal stenosis with degenerative spondylolisthesis: a pragmatic comparative noninferiority observational study from the Norwegian Registry for Spine Surgery.","volume":"26","author":"Austevoll","year":"2017","journal-title":"Eur Spine J"},{"issue":"6","key":"noi230035r14","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1177\/1352458506070775","article-title":"MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis.","volume":"12","author":"Butzkueven","year":"2006","journal-title":"Mult Scler"},{"issue":"1","key":"noi230035r15","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.v11.1","article-title":"The Danish Multiple Sclerosis Registry.","volume":"11","author":"Magyari","year":"2021","journal-title":"Brain Behav"},{"issue":"4","key":"noi230035r16","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1177\/1352458516657439","article-title":"Neurostatus e-scoring improves consistency of Expanded Disability Status Scale assessments: a proof of concept study.","volume":"23","author":"D\u2019Souza","year":"2017","journal-title":"Mult Scler"},{"issue":"5","key":"noi230035r17","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1177\/1352458516662728","article-title":"Data quality evaluation for observational multiple sclerosis registries.","volume":"23","author":"Kalincik","year":"2017","journal-title":"Mult Scler"},{"issue":"1","key":"noi230035r18","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/j.1749-6632.1965.tb20235.x","article-title":"Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis.","volume":"122","author":"Schumacher","year":"1965","journal-title":"Ann N Y Acad Sci"},{"issue":"pt 11","key":"noi230035r19","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1093\/brain\/awv258","article-title":"Defining reliable disability outcomes in multiple sclerosis.","volume":"138","author":"Kalincik","year":"2015","journal-title":"Brain"},{"issue":"387","key":"noi230035r20","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1080\/01621459.1984.10478078","article-title":"Reducing bias in observational studies using subclassification on the propensity score.","volume":"79","author":"Rosenbaum","year":"1984","journal-title":"J Am Stat Assoc"},{"issue":"1","key":"noi230035r21","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.annepidem.2013.10.007","article-title":"Missing data in longitudinal studies: cross-sectional multiple imputation provides similar estimates to full-information maximum likelihood.","volume":"24","author":"Ferro","year":"2014","journal-title":"Ann Epidemiol"},{"key":"noi230035r22","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.neuroimage.2015.06.037","article-title":"Using multiple imputation to efficiently correct cerebral MRI whole brain lesion and atrophy data in patients with multiple sclerosis.","volume":"119","author":"Chua","year":"2015","journal-title":"Neuroimage"},{"issue":"2","key":"noi230035r23","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/pst.v10.2","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies.","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm Stat"},{"issue":"9","key":"noi230035r28","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1177\/1352458518757930","article-title":"Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis\u2014yes.","volume":"24","author":"Piehl","year":"2018","journal-title":"Mult Scler"},{"issue":"9","key":"noi230035r29","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1177\/1352458518757931","article-title":"Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis\u2014no.","volume":"24","author":"Wallin","year":"2018","journal-title":"Mult Scler"},{"issue":"14","key":"noi230035r30","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1056\/NEJMra1510063","article-title":"Challenges in the design and interpretation of noninferiority trials.","volume":"377","author":"Mauri","year":"2017","journal-title":"N Engl J Med"},{"issue":"24","key":"noi230035r31","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1001\/jama.2012.87802","article-title":"Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement.","volume":"308","author":"Piaggio","year":"2012","journal-title":"JAMA"},{"issue":"9805","key":"noi230035r32","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0140-6736(11)61649-8","article-title":"Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.","volume":"378","author":"Kappos","year":"2011","journal-title":"Lancet"},{"issue":"7","key":"noi230035r33","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1007\/s00415-022-10989-0","article-title":"Effectiveness of rituximab vs ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study.","volume":"269","author":"Alcal\u00e1","year":"2022","journal-title":"J Neurol"},{"issue":"2","key":"noi230035r34","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1177\/13524585211047080","article-title":"ECTRIMS 2021\u2014late breaking news ePoster.","volume":"27","author":"Roos","year":"2021","journal-title":"Mult Scler J"},{"key":"noi230035r35","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102802","article-title":"Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis.","volume":"49","author":"Capasso","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"13","key":"noi230035r36","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1177\/1352458516653667","article-title":"Observational data: Understanding the real MS world.","volume":"22","author":"Kalincik","year":"2016","journal-title":"Mult Scler"},{"key":"noi230035r24","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3692-2","volume-title":"Observational Studies (Springer Series in Statistics)","author":"Rosenbaum","year":"2002","edition":"2nd ed"},{"key":"noi230035r1","unstructured":"World Health Organization. WHO model list of essential medicines. Accessed October 11, 2022. https:\/\/www.who.int\/medicines\/publications\/essentialmedicines\/en\/"},{"key":"noi230035r25","unstructured":"US Department of Health and Human Services. Noninferiority clinical trials to establish effectiveness: guidance for industry. Accessed October 10, 2022. https:\/\/www.fda.gov\/media\/78504\/download"},{"key":"noi230035r26","unstructured":"Ocrelizumab Versus Rituximab Off-Label at the Onset of Relapsing MS Disease (OVERLORD-MS). Updated October 18, 2022. Accessed November 1, 2022, https:\/\/ClinicalTrials.gov\/show\/NCT04578639"},{"key":"noi230035r27","unstructured":"Noninferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis (DanNORMS). Updated May 4, 2022. Accessed October 11, 2022. https:\/\/ClinicalTrials.gov\/show\/NCT04688788"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2806000\/jamaneurology_roos_2023_oi_230035_1692383926.80336.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T11:00:48Z","timestamp":1692615648000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2806000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2023.1625","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,1]]}}}